GLYBURIDE (MICRONIZED)
LOE ApproachingNDAORALTABLET
Approved
Apr 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glyburide (micronized) is an oral second-generation sulfonylurea approved in 1992 for type 2 diabetes management. It works by stimulating pancreatic beta cells to increase insulin secretion, lowering blood glucose levels. The micronized formulation improves bioavailability compared to conventional glyburide.
LOE Approaching
Loss of exclusivity is imminent; brand team focus likely shifting to managed care defense and generic transition planning with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on glyburide offers limited career advancement given its LOE-approaching status and mature market position with minimal innovation. This role is best suited for professionals managing mature portfolio assets or planning generic transition strategies rather than those seeking growth-stage product exposure.
Brand ManagerProduct Manager
Worked on GLYBURIDE (MICRONIZED) at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.